Molecular Imaging Study Reveals Improved Detection of Early Stage Recurrent Prostate Cancer

Molecular Imaging Study Reveals Improved Detection of Early Stage Recurrent Prostate Cancer
Molecular Imaging Study Reveals Improved Detection of Early Stage Recurrent Prostate Cancer

The use of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) significantly increases the risk for developing severe and fatal infections in patients with cancer, a recent study published in the journal OncoTargets and Therapy has shown.

VEGFR-TKIs, such as axitinib, pazopanib, regorafenib, sorafenib, and sunitinib, are widely used for the treatment of a variety of solid tumors, including colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. However, concerns have arisen surrounding the association between these agents and the risk of severe infections. Therefore, researchers at The General Hospital of Tianjin Medical University in China sought to evaluate the contribution of VEGFR-TKIs to the risk of infections.

For the meta-analysis, researchers analyzed data from 27 randomized controlled trials that included a total of 16,488 patients. Results showed that the risk for severe and fatal infections was significantly higher in patients who received VEGFR-TKIs compared with controls. Subgroup analyses demonstrated no difference in risk between patients with different tumor types or agent used.

The findings suggest that health care professionals should closely monitor patients treated with VEGFR-TKIs for any signs of infection, particularly those with non-small cell lung cancer and colorectal cancer.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs